ASCO 临时临床意见：KRAS、西妥昔单抗和帕尼单抗在结直肠癌中的临床意义。
ASCO Provisional Clinical Opinion: KRAS, Cetuximab, and Panitumumab-Clinical Implications in Colorectal Cancer.
出版信息
J Oncol Pract. 2009 Mar;5(2):71-2. doi: 10.1200/JOP.0924603.
Abstract
ASCO's Provisional Clinical Opinion alerts oncologists to emerging information from recent clinical trials that can assist them in treatment selection. Evidence suggests that cetuximab and panitumumab are ineffective in patients with KRAS mutations at codon 12 or 13. Thus, patients with colorectal cancer with these mutations should be spared the toxicity and cost of an ineffective therapy.
摘要
ASCO 的临时临床意见提醒肿瘤学家注意最近临床试验中出现的新信息，这些信息可以帮助他们进行治疗选择。有证据表明，西妥昔单抗和帕尼单抗对密码子 12 或 13 发生 KRAS 突变的患者无效。因此，患有这些突变的结直肠癌患者应该避免无效治疗的毒性和费用。
相似文献
1
ASCO Provisional Clinical Opinion: KRAS, Cetuximab, and Panitumumab-Clinical Implications in Colorectal Cancer.
J Oncol Pract. 2009 Mar;5(2):71-2. doi: 10.1200/JOP.0924603.
2
American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy.
J Clin Oncol. 2009 Apr 20;27(12):2091-6. doi: 10.1200/JCO.2009.21.9170. Epub 2009 Feb 2.
3
KRAS Testing for Anti-EGFR Therapy in Advanced Colorectal Cancer: An Evidence-Based and Economic Analysis.
Ont Health Technol Assess Ser. 2010;10(25):1-49. Epub 2010 Dec 1.
4
The clinical effectiveness and cost-effectiveness of cetuximab (mono- or combination chemotherapy), bevacizumab (combination with non-oxaliplatin chemotherapy) and panitumumab (monotherapy) for the treatment of metastatic colorectal cancer after first-line chemotherapy (review of technology appraisal No.150 and part review of technology appraisal No. 118): a systematic review and economic model.
Health Technol Assess. 2013 Apr;17(14):1-237. doi: 10.3310/hta17140.
5
Recommendations from the EGAPP Working Group: can testing of tumor tissue for mutations in EGFR pathway downstream effector genes in patients with metastatic colorectal cancer improve health outcomes by guiding decisions regarding anti-EGFR therapy?
Genet Med. 2013 Jul;15(7):517-27. doi: 10.1038/gim.2012.184. Epub 2013 Feb 21.
6
Clinical and economic value of screening for Kras mutations as predictors of response to epidermal growth factor receptor inhibitors.
Am J Health Syst Pharm. 2009 Dec 1;66(23):2105-12. doi: 10.2146/ajhp090036.
7
American Society of Clinical Oncology provisional clinical opinion: epidermal growth factor receptor (EGFR) Mutation testing for patients with advanced non-small-cell lung cancer considering first-line EGFR tyrosine kinase inhibitor therapy.
J Clin Oncol. 2011 May 20;29(15):2121-7. doi: 10.1200/JCO.2010.31.8923. Epub 2011 Apr 11.
8
American Society of Clinical Oncology provisional clinical opinion: the integration of palliative care into standard oncology care.
J Clin Oncol. 2012 Mar 10;30(8):880-7. doi: 10.1200/JCO.2011.38.5161. Epub 2012 Feb 6.
9
Economic Analysis of Panitumumab Compared With Cetuximab in Patients With Wild-type KRAS Metastatic Colorectal Cancer That Progressed After Standard Chemotherapy.
Clin Ther. 2016 Jun;38(6):1376-1391. doi: 10.1016/j.clinthera.2016.03.023. Epub 2016 Apr 13.
10
Panitumumab in patients with KRAS wild-type colorectal cancer after progression on cetuximab.
Oncologist. 2012;17(1):14. doi: 10.1634/theoncologist.2011-0452. Epub 2011 Dec 30.
引用本文的文献
1
Phase I first-in-human study of HLX07, a novel and improved recombinant anti-EGFR humanized monoclonal antibody, in patients with advanced solid cancers.
Invest New Drugs. 2021 Oct;39(5):1315-1323. doi: 10.1007/s10637-021-01099-1. Epub 2021 Mar 13.
2
Cetuximab in Patients with Breast Cancer, Non-Small Cell Lung Cancer, and Ovarian Cancer Without KRAS, NRAS, or BRAF Mutations: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study.
Target Oncol. 2020 Dec;15(6):733-741. doi: 10.1007/s11523-020-00753-7.
3
Adapting Practice in the Face of New Data.
J Oncol Pract. 2009 Mar;5(2):83-85. doi: 10.1200/JOP.0922501.
4
Testing, Tumor Location, and Survival in Patients With Stage IV Colorectal Cancer: SEER 2010-2013.
J Natl Compr Canc Netw. 2017 Dec;15(12):1484-1493. doi: 10.6004/jnccn.2017.7011.
5
Clinical Pharmacogenetic Testing and Application: Laboratory Medicine Clinical Practice Guidelines.
Ann Lab Med. 2017 Mar;37(2):180-193. doi: 10.3343/alm.2017.37.2.180.
6
Comparison of KRAS and PIK3CA gene status between primary tumors and paired metastases in colorectal cancer.
Onco Targets Ther. 2016 Apr 20;9:2329-35. doi: 10.2147/OTT.S97668. eCollection 2016.
7
PRMT1-mediated methylation of the EGF receptor regulates signaling and cetuximab response.
J Clin Invest. 2015 Dec;125(12):4529-43. doi: 10.1172/JCI82826. Epub 2015 Nov 16.
8
Factors Associated With Guideline-recommended KRAS Testing in Colorectal Cancer Patients: A Population-based Study.
Am J Clin Oncol. 2017 Oct;40(5):498-506. doi: 10.1097/COC.0000000000000191.
9
Anti-IGF-1R monoclonal antibody inhibits the carcinogenicity activity of acquired trastuzumab-resistant SKOV3.
J Ovarian Res. 2014 Nov 26;7:103. doi: 10.1186/s13048-014-0103-5.
10
Analysis of stage and clinical/prognostic factors for colon and rectal cancer from SEER registries: AJCC and collaborative stage data collection system.
Cancer. 2014 Dec 1;120 Suppl 23(0 0):3793-806. doi: 10.1002/cncr.29056.
本文引用的文献
1
American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy.
J Clin Oncol. 2009 Apr 20;27(12):2091-6. doi: 10.1200/JCO.2009.21.9170. Epub 2009 Feb 2.
2
K-ras mutations and benefit from cetuximab in advanced colorectal cancer.
N Engl J Med. 2008 Oct 23;359(17):1757-65. doi: 10.1056/NEJMoa0804385.
3
Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer.
J Clin Oncol. 2008 Apr 1;26(10):1626-34. doi: 10.1200/JCO.2007.14.7116. Epub 2008 Mar 3.
4
A randomised phase III study on capecitabine, oxaliplatin and bevacizumab with or without cetuximab in first-line advanced colorectal cancer, the CAIRO2 study of the Dutch Colorectal Cancer Group (DCCG). An interim analysis of toxicity.
Ann Oncol. 2008 Apr;19(4):734-8. doi: 10.1093/annonc/mdm607. Epub 2008 Feb 13.
5
KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab.
J Clin Oncol. 2008 Jan 20;26(3):374-9. doi: 10.1200/JCO.2007.12.5906.
6
KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab.
Ann Oncol. 2008 Mar;19(3):508-15. doi: 10.1093/annonc/mdm496. Epub 2007 Nov 12.
7
Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy.
Br J Cancer. 2007 Apr 23;96(8):1166-9. doi: 10.1038/sj.bjc.6603685. Epub 2007 Mar 20.
8
Targeting the epidermal growth factor receptor for cancer therapy.
J Clin Oncol. 2002 Sep 15;20(18 Suppl):1S-13S.
Zotero 插件